126 related articles for article (PubMed ID: 29605422)
1. Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma.
Hanna C; Villa D; Irani C; Ghosn M; El Rassy E
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e197-e200. PubMed ID: 29605422
[No Abstract] [Full Text] [Related]
2. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
3. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?
Dalia S; Price S; Forsyth P; Sokol L; Jaglal M
Leuk Lymphoma; 2015 Feb; 56(2):500-2. PubMed ID: 24882264
[No Abstract] [Full Text] [Related]
4. Systemic anaphylactic reaction following intrathecal administration of methotrexate in adult patient with primary central nervous system lymphoma.
Elkiran ET; Altundag K; Aksoy S; Onal IK; Tekuzman G
Am J Hematol; 2004 Apr; 75(4):265. PubMed ID: 15054831
[No Abstract] [Full Text] [Related]
5. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
7. Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic lymphoma.
Kohli A; Ferencz TM; Calderon JG
Allergy Asthma Proc; 2004; 25(4):249-52. PubMed ID: 15510585
[TBL] [Abstract][Full Text] [Related]
8. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
Shah AC; Kelly DR; Nabors LB; Oakes WJ; Hilliard LM; Reddy AT
Pediatr Blood Cancer; 2010 Dec; 55(6):1227-30. PubMed ID: 20882580
[TBL] [Abstract][Full Text] [Related]
9. Systemic high-dose intravenous methotrexate for central nervous system metastases.
Lassman AB; Abrey LE; Shah GD; Panageas KS; Begemann M; Malkin MG; Raizer JJ
J Neurooncol; 2006 Jul; 78(3):255-60. PubMed ID: 16344918
[TBL] [Abstract][Full Text] [Related]
10. Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma.
Xie H; Peereboom DM
J Clin Oncol; 2012 Jul; 30(21):e192-4. PubMed ID: 22711852
[No Abstract] [Full Text] [Related]
11. Methotrexate-induced systemic vasculitis.
Yoruk A; Cizmecioglu F; Yukselgungor H; Timur C; Baydilli H; Ozcay S
Med Pediatr Oncol; 2002 Feb; 38(2):139-40. PubMed ID: 11813187
[No Abstract] [Full Text] [Related]
12. Anaphylactoid reaction to high-dose methotrexate and re-administration after a successful desensitization.
Caldeira T; Costa V; Silva I; Oliva T; Norton L
Pediatr Hematol Oncol; 2008 Mar; 25(2):131-4. PubMed ID: 18363180
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
14. Leukocytoclastic vasculitis associated with methotrexate therapy.
Düzova A; Soysal A; Ozen S; Akyüz C; Gököz A; Yetgin S
Turk J Pediatr; 2000; 42(3):267-8. PubMed ID: 11105634
[No Abstract] [Full Text] [Related]
15. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
16. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
Joerger M; Huitema AD; Illerhaus G; Ferreri AJ
Leuk Lymphoma; 2012 Oct; 53(10):1867-75. PubMed ID: 22530664
[TBL] [Abstract][Full Text] [Related]
17. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
18. Leukocytoclastic vasculitis induced by low-dose methotrexate: in vitro evidence for an immunologic mechanism.
Halevy S; Giryes H; Avinoach I; Livni E; Sukenik S
J Eur Acad Dermatol Venereol; 1998 Jan; 10(1):81-5. PubMed ID: 9552765
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
